LUMIGAN

This brand name is authorized in United States. It is also authorized in Australia, Austria, Brazil, Canada, Croatia, Ecuador, Estonia, Finland, France, Germany, Hong Kong SAR China, Ireland, Italy, Japan, Lithuania, Mexico, Netherlands, New Zealand, Poland, Romania, Singapore, Spain, Tunisia, Turkey, UK.

Active ingredients

The drug LUMIGAN contains one active pharmaceutical ingredient (API):

1	Bimatoprost UNII QXS94885MZ - BIMATOPROST
	Bimatoprost is a potent ocular hypotensive agent. It is a synthetic prostamide, structurally related to prostaglandin F2α (PGF2α), that does not act through any known prostaglandin receptors.
	Read more about Bimatoprost

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
LUMIGAN Eye drops, solution	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
S01EE03	Bimatoprost	S Sensory organs → S01 Ophthalmologicals → S01E Antiglaucoma preparations and miotics → S01EE Prostaglandin analogues
Discover more medicines within S01EE03

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
AU	Pharmaceutical Benefits Scheme	10046R, 10053D, 5551E, 8620Q
BR	Câmara de Regulação do Mercado de Medicamentos	501003601171312, 501003602176318, 501006601138311, 501006602134318
CA	Health Products and Food Branch	02324997
DE	Bundesinstitut für Arzneimittel und Medizinprodukte	00265425, 01682007, 02667168, 02667205, 04446112, 05900524, 05900530, 06846264, 07111493, 10070148, 10070154, 10114756, 10114762, 10199497, 10353389, 10402538, 10408937, 10418137, 10637626, 10742004, 11522397, 11522405, 11542371, 12342935, 13350693, 14032995, 14215916, 14241144, 14275574, 15634182, 15656344, 17199253, 17558516
EC	Agencia Nacional de Regulación, Control y Vigilancia Sanitaria	25.847-08-04, 30173-04-12
EE	Ravimiamet	1198289, 1198290, 1459896, 1459908, 1612022, 1612033, 1638154
ES	Centro de información online de medicamentos de la AEMPS	02205003, 02205003IP, 102205006
FI	Lääkealan turvallisuus- ja kehittämiskeskus	007275, 010706, 115209, 181536
FR	Base de données publique des médicaments	60135981, 66203859
GB	Medicines & Healthcare Products Regulatory Agency	167478, 167479, 219097, 375928, 376738, 381475
HK	Department of Health Drug Office	60394, 62570
IE	Health Products Regulatory Authority	41901, 77154, 77404, 77432
IT	Agenzia del Farmaco	035447022, 035447059
JP	医薬品医療機器総合機構	1319757Q1027
LT	Valstybinė vaistų kontrolės tarnyba	1005610, 1029636, 1052831, 1052832, 1068565, 1068566, 1071583
MX	Comisión Federal para la Protección contra Riesgos Sanitarios	467M2001
NL	Z-Index G-Standaard	14748444
NL	Z-Index G-Standaard, PRK	104655, 61506, 92681
NZ	Medicines and Medical Devices Safety Authority	10164, 13594, 15430
PL	Rejestru Produktów Leczniczych	100127269, 100221672
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W68880001, W68880002
SG	Health Sciences Authority	14365P
TN	Direction de la Pharmacie et du Médicament	3983011, 3983012
TR	İlaç ve Tıbbi Cihaz Kurumu	8699490561287
US	FDA, National Drug Code	0023-3205